medigraphic.com
ISSN 1561-3011 (Electronic)

2020, Number 4

<< Back Next >>

Rev Cubana Invest Bioméd 2020; 39 (4)

Uric acid and gamma-glutamyltransferase as biomarkers of cardiovascular disease via oxidative stress

Rodríguez-Guzmán R, Céspedes MEM, Suárez CN

Language: Spanish
References: 42
Page: 1-15
PDF size: 294.24 Kb.


ABSTRACT

Introduction: Cardiovascular diseases are the leading cause of mortality and morbidity worldwide. Recognized as a health problem of social impact; they have prompted many scientists to try to explain their pathogenesis. New risk factors are currently acknowledged alongside the classic ones. These factors include the role of high uric acid concentrations and the activity of the enzyme gamma-glutamyltransferase in blood, both of which are biomarkers of oxidative stress. These elements may individually contribute to the development of cardiovascular diseases, and seem to have a synergistic effect.
Objective: Review the evidence supporting the idea that high uric acid concentrations and the activity of the enzyme gamma-glutamyltransferase in blood may be risk factors contributing to the development of cardiovascular diseases via oxidative stress.
Methods: Data were collected from the databases of various search engines (Medline-Pubmed, Cochrane, Scopus and SciELO) from 1 March 2019 to 23 May 2020.
Conclusions: It was found that uric acid and gamma-glutamyltransferase are hormetic products causing an antioxidant effect on the organism at low concentrations. However, when concentrations rise, they are involved in the occurrence of oxidative processes leading to endothelial dysfunction and cardiovascular diseases.


REFERENCES

  1. Scioli GM, D'Amico F, Rodríguez Guzmán R, Céspedes Miranda EM, Orlandi A. Oxidative stress-induced endothelial dysfunction contributes to cardiovascular disease. Rev Cub Inv Biomed. 2019 [acceso: 09/09/2019]; 38(1). Disponible en: http://www.revibiomedica.sld.cu/index.php/ibi/article/view/168

  2. Cuba. Ministerio de Salud Pública, Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2018. La Habana: Ministerio de Salud Pública; 2019.

  3. Vilches E, Ochoa LA, González M, Ramos L, Tamayo ND, García D. Impacto de la hipertensión arterial esencial y la cardiopatía isquémica en víctimas de muerte cardíaca súbita. Rev Cub Salud Pub. 2016 [acceso: 09/09/2019]; 42(3):432-41. Disponible en: https://www.scielosp.org/pdf/rcsp/2016.v42n3/432-441/es

  4. Patel P, Ordunez P, DiPette D, Escobar MC, Hassell T, Wyss F, et al. For the Standardized Hypertension Treatment and Prevention Network. Improved Blood Pressure Control to Reduce Cardiovascular Disease Morbidity and Mortality: The Standardized Hypertension Treatment and Prevention Project. J Clin Hypertens (Greenwich). 2016 [acceso: 09/09/2019]; 18(12):1284-94. Disponible en: https://www.scielosp.org/article/ssm/content/raw/?resource_ssm_path=/media/assets/rpsp/v41/1020-4989-RPSP-41-1.pdf

  5. Cabrera E, Parlá J, Ncogo JO, Lezcano SE, Rodríguez J, Echevarría EV. Relación del riesgo cardiovascular global con el ácido úrico y algunos componentes del síndrome metabólico. Rev Cub Endocrinol. 2018 [acceso: 09/09/2019]; 29(2) Disponible en: https://scielo.sld.cu/pdf/end/v29n2/end04218.pdf

  6. Céspedes Miranda EM, Rodríguez Guzmán R, Suárez Castillo N. Gamma-glutamiltransferasa y enfermedad cardiovascular. ArchHosp Calixto García. 2019 [acceso: 09/09/2019]; 7(2):260-73. Disponible en: http://revcalixto.sld.cu/index.php/ahcg/article/view/366

  7. Dogan A, Arsian A, Yucel H, Aksoy F, Icli A, Ozaydin M, et al. Gamma-glutamyltransferase, inflammation and cardiovascular risk factors in isolated coronary artery ectasia. Rev Port Cardiol. 2016 [acceso: 09/09/2019]; 35(1):33-9. Disponible en: https://www.sciencedirect.com/science/article/pii/S2174204916000040

  8. Vidanapathirana DM, Jasinge EA, Saramanayake D, Wickramasinghe P. Association of serum uric acid and gamma-glutamyltransferase with obesity related metabolic derangements in a cohort of children with obesity in Sri Lanka. Ceylon Medical J. 2019;64:125-32.

  9. Luño J, Goicochea M, García-de Vinuesa S. Introducción: avances en el tratamiento de la gota. Nefrología Sup Ext. 2012;3(2):1-7.

  10. Vázquez-Ávila JA, Zetina- Martínez M, Duarte-Mote J. Hiperuricemia e hipertensión arterial sistémica: ¿cuál es la relación? Med Intern Mex. 2018 [acceso: 09/09/2019]; 34(2):378-87. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0186-48662018000200009&lng=es

  11. Rahimi- Sakak F, Maroofi M, Rahamani J, Bellissimo N, Hekmatdoost A. Serum uric acid and risk of cardiovascular mortality: a systematic review and dose - response meta-analysis of cohort studies of over a million participants. BMC CardiovascularDisorders. 2019;19(1):218-26.

  12. Cibicoka L, Karadasek D. Uric acid as a risk factor for cardiovascular diseases. Vnitr Lek. 2016;62(11):919-23.

  13. Chang CC, Wu CH, Liu LK, Chou RS, Kuo CS, Huang PH. Association between serum uric acid and cardiovascular risk in non hypertensive and non diabetic individuals: The Taiwan I-Lan Longitudinal Aging Study. Asia Pac J Public Health. 2018;8:5234.

  14. Radovanic S, Savic- Radojevic A, Pekmezovic T, Markovic T, Memom L, Jelic S, et al. El ácido úrico y la actividad de gamma-glutamiltransferasa se asocian a los índices de remodelado ventricular izquierdo en pacientes con insuficiencia cardíaca crónica. RevEspCardiol. 2014;67(8);632-42.

  15. Lee S, Kim K, Kim KN. Combined effect of serum gamma-glutamyltransferase and uric acid on incidence of Diabetes Mellitus. A longitudinal study. Medicine. 2017 [acceso: 09/09/2019]; 96(17):e6901. Disponible en: https://europepmc.org/article/med/28489802

  16. Global Health Estimates 2015: Deaths by Cause, Age, Sex, by Country and by Region, 2000- 2015. Geneva, World Health Organization; 2016. [acceso: 09/09/2019]. Disponible en: Disponible en: http://www.who.int/health info/global_burden_ disease/estimates/en/index1.html

  17. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the Epidemiology of Cardiovascular Disease: A Historical Perspective. Lancet. 2014;383;(9921):999-1008. DOI: 10.1016/s0140-6736(13)617523

  18. Ifeany OE. A review on free radicals and antioxidants. IntJ Curr ResMed Sci. 2018;4:123-33.

  19. Galina MA, Ortiz M, Guerrero M. Estrés oxidativo y antioxidantes. Avanc Invest Agrop. 2018;22(1):47-61.

  20. Mohammed MT, Kadhim SM, Noori AM, Abbas J, Abbas SI. Free radicals and human health. Internat J Innov Sci Res. 2015;4(6):218-23.

  21. Céspedes EM, Rodríguez R, Suárez N. Ácidoúrico y estrés oxidativo contribuyen a la enfermedad cardiovascular a través de la disfunción endotelial y la insulinorresistencia. Rev Cub Invest Biomed. 2019 [acceso: 09/09/2019]; 38(4).Disponible en: http://www.revibiomedica.sld.cu/index.php/ibi/article/view/241

  22. Ortakoygoglu A, Boz B, Dizdar OS, Avci D, Cetinkaya Ali, Baspinar O. The association of serum gamma-glutamyltrasnpeptidase level and other laboratory parameters with blood pressure in hypertensive patients under ambulatory blood pressure monitoring. Therap Clin Risk Manag. 2016; 12:1395-401.

  23. Incalza MA, D'Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. VascPharmacol. 2018;100:1-19. DOI: 10.1016/j.vph.2017.05.005

  24. Gao L, Thakur A, Siu PM, Lai CWK. Role of free fatty acids in endothelial dysfunction. J Biomed Sci. 2017;24(1):50. DOI: 10.1186/s12929-017-0357-5

  25. Tesauro M, Mauriello A, Rovella V, Annicchiarico-Petruzzelli M, Cardillo C. Arterial ageing: from endothelial dysfunction to vascular calcification. J Intern Med. 2017;281;471-82. DOI: 10.1111/joim.12605

  26. Watt J, Kennedy S, Ahmed N, Hayhurst J, McClure JD, Berry C. The relationship between oxidized LDL, endothelial progenitor cells and coronary endothelial function in patients with CHD. Open Heart. 2016;3(1):e000342. DOI: 10.1136/openhrt-2015-000342

  27. Zhu W, Yuan Y, Liao G. Mesenchymal stem cells ameliorate hyperglycemia-induced endothelial injury through modulation of mitophagy. Cell Death Dis. 2018 [acceso: 09/09/2019]; 837:9. https://www.nature.com/articles/s41419-018-0861-x

  28. Piepoli FM, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315-81. DOI: 10.1093/eurheartj/ehw106

  29. Rodríguez-Guzmán R, Guzmán P, Dorta-Contreras AJ. Estrés oxidativo y epigenética en la obesidad, el síndrome metabólico y la percepción olfativa. RevNeurol.2020;70(7):270.

  30. Vargas Z, Flammar AJ, Steiger P, Haberecker M, Andermatt R, Zinckernagel AS. Endothelial cell infection and endothelitis in COVID-19. The Lancet. 2020;395(10234):1417-8. DOI: 10.1016/S0140-6736(20)30937-5

  31. Vargas G. Ácido úrico y síndrome metabólico: "causa o efecto". Arch Medic Familiar. 2017;19(4):155-69.

  32. Arocha JI, Amair P, Navarrete LM, López D, Amarista F, Straga J. Implicaciones del ácido úrico en el riesgo cardiovascular. Avances Cardiol. 2014;34(3):239-51.

  33. Cebollada J, Gimeno JA. Ácido úrico como factor de riesgo cardiovascular. Hipertensión y Risgo Vascular. 2012;29(2):36-43.

  34. Gaubert M, Marlinge M, Alessandrini M, Laine M, Bonello L, Fromonot J, et al. Uric acid levels are associated with endothelial dysfunction and severity of coronary atherosclerosis during a first episode of acute coronary syndrome. Purinergic Signal. 2018;14(2):191-9. DOI: 10.1007/s11302-018-9604-9

  35. Qin L, Yon Z, Kehui D, Anxin W, Xing Y, Caifeng Z, et al. The association between serum uric acid levels and the prevalence of vulnerable atherosclerotic carotid plaque: a cross sectional study. Sci Rep. 2015(11);5:10003. DOI: 10.1038/srep10003

  36. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000 [acceso: 09/09/2019]; 283(18):2404-10. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/10815083

  37. Villanueva J, Huerta S, Huerta D, Lozada CA. Asociación entre la elevación sérica de gamma-glutamiltranspeptidasa y riesgo aumentado de evento vascular cerebral isquémico en población mexicana. Med Int Mexico. 2019;35(3):337-43.

  38. Seo Y, Aonuma K. Gamma-glutamiltransferaseis a biomarker risk for cardiovascular disease. Circ J. 2017;81:783-5

  39. Kim JG, Chang K, Choo EH, Lee JM, Seung KB. Serum gamma-glutamyl transferase is a predictor of mortality in patients with acute myocardial infarction. Medicine. 2018 acceso: 09/09/2019; 97(29):e11393. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086492/pdf/medi-97-e11393.pdf

  40. Franzini M, Forniaciari I, Rong J, Larson MG, Passino C, Emdin M, et al. Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham Heart Study. Clin Chim Acta. 2013 [acceso: 09/09/2019]; 417:19-25. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154585/pdf/nihms-609045.pdf

  41. Yunus YM, Muniandy W, Lai HI. Comparison of serum uric acid and gamma-glutamyltranspeptidase level in obese and non-obese individuals. Int J Acad Res Bus Soc Sci. 2017 [acceso: 09/09/2019]; 7:3 Disponible en: http://hrmars.com/hrmars_papers/Comparison_of_Serum_Uric_Acid_and_Gamma-Glutamyltranspeptidase_%28GGT%29_Level_in_Obese_Individuals_and_Non-Obese_Individual.pdf

  42. Bertoli S, Leone A, Vignati L, Spadafranca A, Bedogni G, Vanzulli A, et al. Metabolic correlates of subcutaneous and visceral abdominal fat measured by ultrasonography: a comparisson with waist circunference. Nutr J. 2016 [acceso: 09/09/2019]; 15:2. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26732788




2020     |     www.medigraphic.com